EYPT

EYEPOINT INC

EYPT·30233G209·US·Common Stock·Healthcare - Biotechnology-13D/G

EYPT (EYEPOINT INC) is held by 107 institutional investors as of Q1 2026. Largest holders: BlackRock, Inc. ($92.5M), FEDERATED HERMES, INC. ($73.1M), FRANKLIN RESOURCES INC ($65.1M). Net institutional sentiment: Bullish.

107
Holders
Avg rating(18 Elite)
$667.8M
Total Value
68% (112)
Fund Consensus
71 buying - 33 selling
EYPTSmart Money Verdict
View all
Held by 107 funds
18 elite
Who's Trading
InsiderRRRibeiro RamiroSell $37KJun 30, 2026
InsiderRRRibeiro RamiroSell $37KJun 30, 2026
ActivistCOCommodore Capital LP5.1%Jun 3, 2026
ActivistPBParadigm BioCapital Advisors LP3.8%May 15, 2026
ActivistADAdage Capital Management, L.P.4.0%May 13, 2026
InsiderRRRibeiro RamiroSell $37KApr 17, 2026
ActivistThe Vanguard GroupThe Vanguard Group0.0%Mar 26, 2026
InsiderDSDuker Jay S.Buy $20KMar 16, 2026
InsiderRRRibeiro RamiroSell $44KMar 4, 2026
InsiderRRRibeiro RamiroSell $37KFeb 17, 2026
13F: Insider & Congress:
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Increased
7.2M(+5.7%)$92.5M0.0%+42.48%
32
Decreased
5.7M(-5.8%)$73.1M0.1%+36.13%
0
Increased
5M(+1.4%)$65.1M0.0%+19.31%
30
Increased
3.6M(+22.6%)$46.4M0.0%-18.08%
35
New
3.6M$45.9M0.0%-19.65%
40
Decreased
3.3M(-29.8%)$42.5M0.1%+12.45%
0
Increased
2.1M(+14.3%)$27M0.0%-14.31%
33
Increased
2M(+4.4%)$25.6M0.0%+16.59%
30
New
1.9M$24.6M0.0%-19.65%
40
Increased
1.7M(+8.2%)$22.4M0.0%+6.11%
31
Increased
1.4M(+141.7%)$18.5M0.0%-11.07%
46
Increased
1.1M(+390.0%)$14.1M0.0%-10.84%
45
New
833,455$10.7M0.0%-19.65%
38
New
793,870$10.2M0.0%-19.65%
38
Decreased
699,706(-44.0%)$9M0.0%+81.60%
0
Increased
676,812(+17.2%)$8.7M0.0%+16.19%
32
Unchanged
674,395$8.7M0.0%-17.72%
0
Decreased
640,123(-1.3%)$8.3M0.0%+7.90%
0
Decreased
509,403(-35.1%)$6.6M0.0%-13.23%
0
New
504,472$6.5M0.0%-19.65%
38

Showing 1-20 of 112

1 / 6

Other Healthcare stocks held by institutions

Data sourced from four SEC data sources: 13F, Form 4, 13D/13G, and STOCK Act. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used